Danaher (NYSE:DHR) today reported financial results for the first quarter ended March 31, 2026, characterized by robust cash flow generation and a landmark announcement regarding its portfolio expansion.
The company reported net earnings of $1 billion, or $1.45 per diluted share on a GAAP basis.
The company’s top-line performance saw revenues rise 3.5% to $6 billion, reflecting steady demand across its core life sciences and diagnostics segments.
On a non-GAAP basis, adjusted diluted earnings per share grew 9.5% to $2.06, comfortably exceeding analyst expectations and demonstrating significant operating leverage within its business units.
In a move that defined the quarter's results, Danaher announced its intention to acquire Masimo, a global leader in noninvasive monitoring technologies and hospital automation.
This acquisition is a mechanical necessity for Danaher as it seeks to deepen its footprint in high-acuity clinical environments and expand its digital health offerings.
The integration of Masimo’s sensing technology is expected to complement Danaher’s existing diagnostics portfolio, creating a more comprehensive clinical workflow solution.
Danaher’s cash flow remains a pillar of its corporate strategy.
The company generated $1.3 billion in operating cash flow during the first quarter, with non-GAAP free cash flow reaching $1.1 billion.
This liquidity position provides the capital required to pursue large-scale M&A while continuing to invest in internal research and development.
Buoyed by the first-quarter performance and the anticipated contributions from its strategic initiatives, management has raised its full-year 2026 adjusted EPS guidance to a range of $8.35 to $8.55.
Furthermore, the company expects non-GAAP core revenue growth of 3% to 6% for the full year.